Clinical Trials
Clinical Research within the Division of Rheumatology
The UCLA Division of Rheumatology coducts innovative biomedical and health-related research studies to advance the understanding and treatment of rheumatic diseases. Our research includes both interventional (treatment-based) and observational trials, supported by the National Institutes of Health (NIH), non-profit organizations, and industry partners.
- Interventional trials assign participants to a treatment or therapy to evaluate its effectiveness and outcomes.
- Observational studies monitor participants in a non-interventional setting to better understand health conditions and disease progression.
This research is an essential part of our mission to improve care, discover new therapies, and better understand the conditions we treat.
We regularly update this page with clinical trials organized by condition. To learn more about participating in a study, please contact our clinical research team at the phone number listed below.
Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD)
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
Study Type Details Principal Investigator(s) Observational CTD-ILD Registry: Any patient with a CTD-ILD.
For more information contact 310-794-2466.
Elizabeth Volkmann, MD, MS Observational PET study of 68Ga-FAPi-46 in patients with interstitial lung disease: An exploratory biodistribution study with histopathology validation: This study aims to explore a novel radiographic assessment measure of fibroblast activation in patients with interstitial lung disease. The results may help us better understand the cause of interstitial lung disease and help us in making informed treatment decisions for patients. All patients with interstitial lung disease are eligible to participate.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS -
There are no upcoming trials for this condition at this time. Please check back for future updates.
Gout
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
Study Type Details Principal Investigator(s) Treatment/Interventional Pegloticase: Recapturing immune tolerance to Pegloticase for the management of tophaceous gout.
For more information contact 310-825-9956.
John FitzGerald, MD, PhD, MBA Observational Transitions in Gout Research Study (TIGER) Study
For more information contact 310-825-9956.
John FitzGerald, MD, PhD, MBA Treatment/Interventional UR+AIMS Gout Wearable Skin Uric Acid Monitor Study
For more information contact 310-825-9956.
John FitzGerald, MD, PhD, MBA -
There are no upcoming trials for this condition at this time. Please check back for future updates.
Myositis
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
Study Type Details Principal Investigator(s) Observational HDL: Evaluation of HDL function in patients with and without rheumatic disease.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional Janssen “Spirea”: A study to evaluate the efficacy and safety of Nipocalimab in participants with active idiopathic inflammatory myopathies.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Observational Longitudinal Cohort Study of Patients with Idiopathic Inflammatory Myopathies
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional Priovant (Valor) "Premier" PVT-2201-301: A study to investigate the efficacy and safety of Brepocitinib in adults with dermatomyositis.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS -
Study Type Details Principal Investigator(s) Treatment/Interventional ARGX-113-2011/2007: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy (ALKIVIA+)
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional Galapagos (GALARISSO): A study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional MINT: Nintedanib plus standard of care immunosuppression versus standard of care immunosuppression alone in patients with progressive fibrotic myositis associated - interstitial lung disease.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional Pfizer C0251006: A study to evaluate the efficacy and safety of PF06823859 in participants with active idiopathic inflammatory myopathies (including participants with active dermatomyositis or polymyositis).
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS
Psoriatic Arthritis & Ankylosing Spondylitis
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
We are not currently enrolling trials for this condition. Please check back for future updates.
-
There are no upcoming trials for this condition at this time. Please check back for future updates.
Rheumatoid Arthritis
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
Study Type Details Principal Investigator(s) Observational Longitudinal Cardiovascular Risk Study of Patients with Rheumatoid Arthritis.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional ACTHAR: Use of ACTHAR in Rheumatoid Arthritis Related Flares.
For more information, contact 310-825-9956.
Veena K. Ranganath, MD, MS, RhMSUS Observational CANNABIS: Cannabis Anonymous Questionnaire in UCLA Rheumatology Patients.
For more information, contact 310-825-9956.
Veena K. Ranganath, MD, MS, RhMSUS Treatment/Interventional RA-PROPR: A real-world comparative effectiveness trial of treatment strategies in patients with rheumatoid arthritis: The RA-PRO Pragmatic Trial (RA-PROPR).
For more information, contact 310-825-9956.
Veena K. Ranganath, MD, MS, RhMSUS -
There are no upcoming trials for this condition at this time. Please check back for future updates.
Scleroderma
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
Study Type Details Principal Investigator(s) Treatment/Interventional Cumberland: A Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Systemic Sclerosis Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
For more information contact 310-825-9682.
Suzanne Kafaja, MD Treatment/Interventional Emerald Health EHP-101: A Study to Assess the Safety, Tolerability, and Preliminary Efficacy of EHP-101 in Patients with Diffuse Cutaneous Systemic Sclerosis.
For more information contact 310-825-9682.
Suzanne Kafaja, MD Observational GRASP: Genome Research in African American Scleroderma Patients (GRASP).
For more information contact 310-825-9682.
Suzanne Kafaja, MD Observational Skin Immune Response and Inflammation: Database and tissue bank aimed at evaluating differences in immune response in health and autoimmunity.
For more information contact 310-825-9682.
Suzanne Kafaja, MD Observational SPIN: The Scleroderma Patient-Centered Intervention Network (SPIN) cohort collecting data on a regular basis related to problems likely to be important for many people living with scleroderma.
For more information contact 310-825-9682.
Suzanne Kafaja, MD Observational Validation of Musculoskeletal Ultrasound in Sclerosis Patients
For more information contact 310-825-9682.
Suzanne Kafaja, MD Treatment/Interventional Amgen: A multicenter trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of HZN-825 in patients with diffuse cutaneous systemic sclerosis (with open-label treatment after 52 weeks).
For more information contact 310-825-9682 or 310-794-1638.
Suzanne Kafaja, MD
Elizabeth Volkmann, MD, MS
Treatment/Interventional GSK: A Study of the efficacy and safety of Belimumab in adults with systemic sclerosis associated interstitial lung disease (BLISSc-ILD).
For more information contact 310-825-9682 or 310-794-1638.
Suzanne Kafaja, MD
Elizabeth Volkmann, MD, MS
Treatment/Interventional 1366-0031: A study in people With systemic sclerosis to test whether Avenciguat (BI 685509) has an effect on lung function and other systemic sclerosis symptoms (VITALISScE™).
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Treatment/Interventional aTyr EFZO-CONNECT: Study to evaluate the efficacy, safety, and tolerability of Efzofitimod in patients with systemic sclerosis (SSc)-related interstitial lung disease (ILD) (SSc-ILD).
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational Biomarkers to Predict Treatment Response in Systemic Sclerosis-Interstitial Lung Disease: This is an NIH-sponsored study to discover novel biomarkers that predict response to therapy and outcomes in patients with systemic sclerosis-related interstitial lung disease. The outcomes of this research will allow us to develop personalized treatment plans for patients. All patients with systemic sclerosis-related interstitial lung disease are eligible to participate.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational CONQUER: Collaborative, National Quality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (Scleroderma)
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational CURESSC - Consortium of Universities to REsearch Scleroderma in Southern California: This study seeks to understand the genetics of systemic sclerosis and how changes in the blood vessels and fibroblasts (cells involved in fibrosis) contribute to skin disease in systemic sclerosis. The results of this study may reveal new treatment targets. Any patient with diffuse systemic sclerosis is eligible to participate.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational The Gut Microbiome as a Screening Tool for ILD in Systemic Sclerosis: This study determines whether systemic sclerosis patients with interstitial lung disease (pulmonary fibrosis) have unique features of their gut microbiome. This study also seeks to determine whether the gut microbiome can be used to screen for the presence of interstitial lung disease in early systemic sclerosis.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Treatment/Interventional PR200-104: Phase 2 safety and efficacy study of Tulisokibart (MK-7240/PRA023) in subjects with systemic sclerosis associated with interstitial lung disease (SSc-ILD) (MK-7240-007) (ATHENA-SSc-ILD).
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational Scleroderma Clinical Trial Consortium: This study examines the gut microbiome of patients with systemic sclerosis from across the world to determine the impact of diet and environment on microbial composition in systemic sclerosis. This study will also evaluate whether the microbiome can serve as a marker of disease activity in systemic sclerosis.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational Systemic Sclerosis Microbiome study: This study examines whether the gut microbiome contributes to the pathogenesis (cause) of systemic sclerosis. All patients with systemic sclerosis are eligible to participate in this study.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS -
Study Type Details Principal Investigator(s) Treatment/Interventional GB44496: A study evaluating the efficacy and safety of Vixarelimab in participants with idiopathic pulmonary fibrosis and in participants with systemic sclerosis-associated interstitial lung disease.
For more information contact 310-825-9682.
Suzanne Kafaja, MD Treatment/Interventional CONQUEST: Platform clinical study for conquering scleroderma (Amlitelimab, BI 1015550, or placebo).
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Treatment/Interventional DAISY: A study to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational Examining the prevalence of psychosocial trauma and stress in patients with Systemic Sclerosis (SSc)
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational Investigating Molecular and Metabolic Signatures in Systemic Sclerosis
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS
Sjögren's Syndrome
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
We are not currently enrolling trials for this condition. Please check back for future updates.
-
There are no upcoming trials for this condition at this time. Please check back for future updates.
Systemic Lupus Erythematosus
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
Study Type Details Principal Investigator(s) Observational Benlysta in Early Lupus: A study to evaluate the effects of Belimumab in patients recently diagnosed with lupus.
For more information contact 310-794-9236.
Maureen McMahon, MD, MS Treatment/Interventional ITN Vibrant: A phase 2a, randomized, placebo-controlled, double-blind multicenter trial of VIB4920 for active lupus nephritis.
For more information contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional Novartis CVAY736K12301: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (SIRIUS-LN).
For more information contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional Novartis CVAY736F12302: Phase 3 extension study to evaluate long-term safety of Ianalumab in participants with systemic lupus erythematosus (SIRIUS-SLE Extension). (SIRIUS-SLE LTE).
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional Poetyk: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Deucravacitinib in participants with active systemic lupus erythematosus (SLE).
For more information contact 310-825-2598.
Maureen McMahon, MD, MS Observational PRiSE: Probing Remission in SLE: Blood and Brain.
For more information, contact 310-794-9236.
Maureen McMahon, MD, MS Observational Pro-inflammatory HDL Cholesterol: Evaluating biomarkers of risk for atherosclerosis in lupus. Involves a one-time blood draw.
For more information contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional SHIELD: Effects of stopping hydroxychloroquine in elderly lupus disease.
For more information contact 310-825-2598.
Maureen McMahon, MD, MS -
Study Type Details Principal Investigator(s) Treatment/Interventional Amgen: A phase 2a, open-label, multi-center, platform trial to assess the safety, tolerability, and efficacy of Inebilizumab and Blinatumomab in subjects with select autoimmune diseases.
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional Artiva: A phase 1 study to evaluate the efficacy and safety of AB-101, an allogeneic cord blood derived NK-Cell therapy in combination with B-Cell depleteing monoclonal antibodies in patients who failed treatment for class II or IV lupus nephritis.
For more information, contact 310-825-2598.
Jennifer Grossman, MD, PhD Treatment/Interventional BMS CA061-1011: A phase 2, multicenter, open-label study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in participants with active SLE (including Lupus Nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants (breakfree-SLE).
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Observational GSK: The evaluation Of use of Belimumab in routine care SEttings in Lupus Nephritis (LN): the OBSErve-LN study.
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional IM026-024: A study evaluating the efficacy and safety of Afimetoran compared with placebo in participants with active systemic lupus erythematosus (SLE).
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Observational Lupus Landmark Study: A prospective registry and biorepository.
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional SNAC: Systemic Lupus Erythematosus (SLE) Treatment with N-acetylcysteine (NAC) - SNAC.
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional Zenas: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obexelimab in patients with systemic lupus erythematosus.
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS
Vasculitis
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
We are not currently enrolling trials for this condition. Please check back for future updates.
-
There are no upcoming trials for this condition at this time. Please check back for future updates.
Current Clinical Studies
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
Study Type Details Principal Investigator(s) Observational CTD-ILD Registry: Any patient with a CTD-ILD.
For more information contact 310-794-2466.
Elizabeth Volkmann, MD, MS Observational PET study of 68Ga-FAPi-46 in patients with interstitial lung disease: An exploratory biodistribution study with histopathology validation: This study aims to explore a novel radiographic assessment measure of fibroblast activation in patients with interstitial lung disease. The results may help us better understand the cause of interstitial lung disease and help us in making informed treatment decisions for patients. All patients with interstitial lung disease are eligible to participate.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS -
Study Type Details Principal Investigator(s) Treatment/Interventional Pegloticase: Recapturing immune tolerance to Pegloticase for the management of tophaceous gout.
For more information contact 310-825-9956.
John FitzGerald, MD, PhD, MBA Observational Transitions in Gout Research Study (TIGER) Study
For more information contact 310-825-9956.
John FitzGerald, MD, PhD, MBA Treatment/Interventional UR+AIMS Gout Wearable Skin Uric Acid Monitor Study
For more information contact 310-825-9956.
John FitzGerald, MD, PhD, MBA -
Study Type Details Principal Investigator(s) Observational HDL: Evaluation of HDL function in patients with and without rheumatic disease.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional Janssen “Spirea”: A study to evaluate the efficacy and safety of Nipocalimab in participants with active idiopathic inflammatory myopathies.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Observational Longitudinal Cohort Study of Patients with Idiopathic Inflammatory Myopathies
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional Priovant (Valor) "Premier" PVT-2201-301: A study to investigate the efficacy and safety of Brepocitinib in adults with dermatomyositis.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS -
There are no open trials for this condition at this time.
-
Study Type Details Principal Investigator(s) Observational Longitudinal Cardiovascular Risk Study of Patients with Rheumatoid Arthritis.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional ACTHAR: Use of ACTHAR in Rheumatoid Arthritis Related Flares.
For more information, contact 310-825-9956.
Veena K. Ranganath, MD, MS, RhMSUS Observational CANNABIS: Cannabis Anonymous Questionnaire in UCLA Rheumatology Patients.
For more information, contact 310-825-9956.
Veena K. Ranganath, MD, MS, RhMSUS Treatment/Interventional RA-PROPR: A real-world comparative effectiveness trial of treatment strategies in patients with rheumatoid arthritis: The RA-PRO Pragmatic Trial (RA-PROPR).
For more information, contact 310-825-9956.
Veena K. Ranganath, MD, MS, RhMSUS -
Study Type Details Principal Investigator(s) Treatment/Interventional Cumberland: A Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Systemic Sclerosis Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
For more information contact 310-825-9682.
Suzanne Kafaja, MD Treatment/Interventional Emerald Health EHP-101: A Study to Assess the Safety, Tolerability, and Preliminary Efficacy of EHP-101 in Patients with Diffuse Cutaneous Systemic Sclerosis.
For more information contact 310-825-9682.
Suzanne Kafaja, MD Observational GRASP: Genome Research in African American Scleroderma Patients (GRASP).
For more information contact 310-825-9682.
Suzanne Kafaja, MD Observational Skin Immune Response and Inflammation: Database and tissue bank aimed at evaluating differences in immune response in health and autoimmunity.
For more information contact 310-825-9682.
Suzanne Kafaja, MD Observational SPIN: The Scleroderma Patient-Centered Intervention Network (SPIN) cohort collecting data on a regular basis related to problems likely to be important for many people living with scleroderma.
For more information contact 310-825-9682.
Suzanne Kafaja, MD Observational Validation of Musculoskeletal Ultrasound in Sclerosis Patients
For more information contact 310-825-9682.
Suzanne Kafaja, MD Treatment/Interventional Amgen: A multicenter trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of HZN-825 in patients with diffuse cutaneous systemic sclerosis (with open-label treatment after 52 weeks).
For more information contact 310-825-9682 or 310-794-1638.
Suzanne Kafaja, MD
Elizabeth Volkmann, MD, MS
Treatment/Interventional GSK: A Study of the efficacy and safety of Belimumab in adults with systemic sclerosis associated interstitial lung disease (BLISSc-ILD).
For more information contact 310-825-9682 or 310-794-1638.
Suzanne Kafaja, MD
Elizabeth Volkmann, MD, MS
Treatment/Interventional 1366-0031: A study in people With systemic sclerosis to test whether Avenciguat (BI 685509) has an effect on lung function and other systemic sclerosis symptoms (VITALISScE™).
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Treatment/Interventional aTyr EFZO-CONNECT: Study to evaluate the efficacy, safety, and tolerability of Efzofitimod in patients with systemic sclerosis (SSc)-related interstitial lung disease (ILD) (SSc-ILD).
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational Biomarkers to Predict Treatment Response in Systemic Sclerosis-Interstitial Lung Disease: This is an NIH-sponsored study to discover novel biomarkers that predict response to therapy and outcomes in patients with systemic sclerosis-related interstitial lung disease. The outcomes of this research will allow us to develop personalized treatment plans for patients. All patients with systemic sclerosis-related interstitial lung disease are eligible to participate.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational CONQUER: Collaborative, National Quality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (Scleroderma)
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational CURESSC - Consortium of Universities to REsearch Scleroderma in Southern California: This study seeks to understand the genetics of systemic sclerosis and how changes in the blood vessels and fibroblasts (cells involved in fibrosis) contribute to skin disease in systemic sclerosis. The results of this study may reveal new treatment targets. Any patient with diffuse systemic sclerosis is eligible to participate.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational The Gut Microbiome as a Screening Tool for ILD in Systemic Sclerosis: This study determines whether systemic sclerosis patients with interstitial lung disease (pulmonary fibrosis) have unique features of their gut microbiome. This study also seeks to determine whether the gut microbiome can be used to screen for the presence of interstitial lung disease in early systemic sclerosis.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Treatment/Interventional PR200-104: Phase 2 safety and efficacy study of Tulisokibart (MK-7240/PRA023) in subjects with systemic sclerosis associated with interstitial lung disease (SSc-ILD) (MK-7240-007) (ATHENA-SSc-ILD).
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational Scleroderma Clinical Trial Consortium: This study examines the gut microbiome of patients with systemic sclerosis from across the world to determine the impact of diet and environment on microbial composition in systemic sclerosis. This study will also evaluate whether the microbiome can serve as a marker of disease activity in systemic sclerosis.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational Systemic Sclerosis Microbiome study: This study examines whether the gut microbiome contributes to the pathogenesis (cause) of systemic sclerosis. All patients with systemic sclerosis are eligible to participate in this study.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS -
There are no open trials for this condition at this time.
-
Study Type Details Principal Investigator(s) Observational Benlysta in Early Lupus: A study to evaluate the effects of Belimumab in patients recently diagnosed with lupus.
For more information contact 310-794-9236.
Maureen McMahon, MD, MS Treatment/Interventional ITN Vibrant: A phase 2a, randomized, placebo-controlled, double-blind multicenter trial of VIB4920 for active lupus nephritis.
For more information contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional Novartis CVAY736K12301: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (SIRIUS-LN).
For more information contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional Novartis CVAY736F12302: Phase 3 extension study to evaluate long-term safety of Ianalumab in participants with systemic lupus erythematosus (SIRIUS-SLE Extension). (SIRIUS-SLE LTE).
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional Poetyk: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Deucravacitinib in participants with active systemic lupus erythematosus (SLE).
For more information contact 310-825-2598.
Maureen McMahon, MD, MS Observational PRiSE: Probing Remission in SLE: Blood and Brain.
For more information, contact 310-794-9236.
Maureen McMahon, MD, MS Observational Pro-inflammatory HDL Cholesterol: Evaluating biomarkers of risk for atherosclerosis in lupus. Involves a one-time blood draw.
For more information contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional SHIELD: Effects of stopping hydroxychloroquine in elderly lupus disease.
For more information contact 310-825-2598.
Maureen McMahon, MD, MS -
There are no open trials for this condition at this time.
Upcoming Clinical Studies
If you are interested in finding out more information about a particular study, please contact the study personnel listed below.
-
There are no upcoming trials for this condition at this time.
-
There are no upcoming trials for this condition at this time.
-
Study Type Details Principal Investigator(s) Treatment/Interventional ARGX-113-2011/2007: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy (ALKIVIA+)
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional Galapagos (GALARISSO): A study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional MINT: Nintedanib plus standard of care immunosuppression versus standard of care immunosuppression alone in patients with progressive fibrotic myositis associated - interstitial lung disease.
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS Treatment/Interventional Pfizer C0251006: A study to evaluate the efficacy and safety of PF06823859 in participants with active idiopathic inflammatory myopathies (including participants with active dermatomyositis or polymyositis).
For more information contact 310-206-4007.
Christina Charles-Schoeman, MD, MS -
There are no upcoming trials for this condition at this time.
-
There are no upcoming trials for this condition at this time.
-
Study Type Details Principal Investigator(s) Treatment/Interventional GB44496: A study evaluating the efficacy and safety of Vixarelimab in participants with idiopathic pulmonary fibrosis and in participants with systemic sclerosis-associated interstitial lung disease.
For more information contact 310-825-9682.
Suzanne Kafaja, MD Treatment/Interventional CONQUEST: Platform clinical study for conquering scleroderma (Amlitelimab, BI 1015550, or placebo).
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Treatment/Interventional DAISY: A study to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis.
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational Examining the prevalence of psychosocial trauma and stress in patients with Systemic Sclerosis (SSc)
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS Observational Investigating Molecular and Metabolic Signatures in Systemic Sclerosis
For more information, contact 310-794-1638.
Elizabeth Volkmann, MD, MS -
There are no upcoming trials for this condition at this time.
-
Study Type Details Principal Investigator(s) Treatment/Interventional Amgen: A phase 2a, open-label, multi-center, platform trial to assess the safety, tolerability, and efficacy of Inebilizumab and Blinatumomab in subjects with select autoimmune diseases.
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional Artiva: A phase 1 study to evaluate the efficacy and safety of AB-101, an allogeneic cord blood derived NK-Cell therapy in combination with B-Cell depleteing monoclonal antibodies in patients who failed treatment for class II or IV lupus nephritis.
For more information, contact 310-825-2598.
Jennifer Grossman, MD, PhD Treatment/Interventional BMS CA061-1011: A phase 2, multicenter, open-label study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in participants with active SLE (including Lupus Nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants (breakfree-SLE).
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Observational GSK: The evaluation Of use of Belimumab in routine care SEttings in Lupus Nephritis (LN): the OBSErve-LN study.
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional IM026-024: A study evaluating the efficacy and safety of Afimetoran compared with placebo in participants with active systemic lupus erythematosus (SLE).
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Observational Lupus Landmark Study: A prospective registry and biorepository.
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional SNAC: Systemic Lupus Erythematosus (SLE) Treatment with N-acetylcysteine (NAC) - SNAC.
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS Treatment/Interventional Zenas: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obexelimab in patients with systemic lupus erythematosus.
For more information, contact 310-825-2598.
Maureen McMahon, MD, MS -
There are no upcoming trials for this condition at this time.